Document Detail


Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
MedLine Citation:
PMID:  20643208     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
The mammalian heart during its development and in response to physiological or pathological stimuli undergoes hypertrophic enlargement, a consequence of an increase in cardiac myocyte size. Cardiac hypertrophy in response to biomechanical stress stimuli may be initially a compensatory event, but gradually becomes a pathological event if the mechanical stress on the myocardium persists. In fact, studies have shown cardiac hypertrophy as a dominant risk factor for the development of heart failure and coronary artery disease. A number of complex signaling cascades were identified that regulate the cardiac hypertrophic response. Much progress has been made previously in identifying various target sites and understanding the molecular and cellular processes that are involved in the development of cardiac hypertrophy and heart failure. This has led drug discovery research in developing effective therapies to treat various cardiovascular diseases. However, the available therapeutic agents for the treatment of heart failure have limited effectiveness in halting the progression of the disease. Therefore, novel therapeutic strategies are being identified to inhibit the development of cardiac hypertrophy before heart failure develops. In this review, we describe multifarious molecular signaling mechanisms involved in the pathogenesis of cardiac hypertrophy, including tumor necrosis factor-α, Wnt/Frizzled signals, calcineurin, mitofusin-2, mitogen-activated protein kinases, Janus kinase, Rho kinase, poly (ADP-ribose) polymerase, transcription factors, oxidative signals and G-protein-coupled-receptor-associated signaling system. Elucidation of signaling cascades that initiate cardiac hypertrophy will open up a new area of research in developing innovative therapeutics for the treatment of pathological cardiac hypertrophy.
Authors:
Pitchai Balakumar; Gowraganahalli Jagadeesh
Related Documents :
12025908 - A case of catecholamine induced heart failure with left ventricular hypertrophy accompa...
9517378 - Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype.
6208988 - Regression of isoproterenol-induced cardiac hypertrophy.
1827058 - Pathophysiology of myocardial perfusion in hypertension.
15140258 - Perioperative risk stratification in non cardiac surgery: role of pharmacological stres...
6695778 - Location of myocardial necrosis as an independent determinant of left ventricular perfo...
Publication Detail:
Type:  Journal Article     Date:  2010-07-17
Journal Detail:
Title:  Pharmacological research : the official journal of the Italian Pharmacological Society     Volume:  62     ISSN:  1096-1186     ISO Abbreviation:  Pharmacol. Res.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-09-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8907422     Medline TA:  Pharmacol Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  365-83     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Department of Pharmacology, SB College of Pharmacy, Sivakasi 626 130, India. pbala2006@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration.
Next Document:  Mapping quantitative traits and strategies to find quantitative trait genes.